Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.

[powerpress]

Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

[powerpress]

Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.

[powerpress]